Canada · Delayed Price · Currency is CAD Onco-Innovations Company Description
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada.
The company’s lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3′-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology.
It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development.
In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Thomas O’Shaughnessy |
Contact Details
Address: 1122 – 4th Street SW Calgary, AB T2R 1M1 Canada | |
| Phone | 848-488-9277 |
| Website | oncoinnovations.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | Cboe Canada |
| Fiscal Year | May - April |
| Reporting Currency | CAD |
| ISIN Number | CA68237C1059 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thomas O’Shaughnessy | Chief Executive Officer |
| David Antony | Chief Financial Officer |